Form 4: Aptevo Therapeutics CEO Marvin White Acquires Shares Through RSU Vesting
Insider Ownership Change
Aptevo Therapeutics Inc.'s President and CEO, Marvin L. White, acquired 10 shares of common stock through the vesting of Restricted Stock Units, increasing his direct ownership to 12 shares.
Summary
- Marvin L. White, President and CEO, and Director of Aptevo Therapeutics Inc. (APVO), acquired 10 shares of common stock.
- This acquisition occurred on July 17, 2025, and resulted from the vesting of Restricted Stock Units (RSUs).
- The RSUs were part of a grant of 30 post-split RSUs made on July 17, 2024, which are set to vest in three approximately equal annual installments.
- Following this transaction, Mr. White directly beneficially owns 12 shares of Aptevo Therapeutics common stock.
- He also directly beneficially owns 20 unvested Restricted Stock Units.
Sentiment
Score: 7
Explanation: The filing indicates a routine, expected transaction where an executive's ownership stake increases due to RSU vesting, which is generally a positive sign of alignment but not indicative of new strategic developments or significant financial performance.
Positives
- Management's ownership stake in the company increased, which generally aligns executive interests with shareholder value.
- The vesting of Restricted Stock Units is a routine compensation event, indicating the executive is meeting the conditions for equity awards.
Future Outlook
The remaining 20 Restricted Stock Units are expected to vest in two approximately equal annual installments following the initial vesting on July 17, 2025.
Industry Context
This filing is a routine disclosure of insider stock ownership changes, common across all publicly traded companies, and does not provide specific industry context beyond the company's name.
Stakeholder Impact
- Shareholders: Increased alignment of executive interests with shareholder value through direct stock ownership.
Next Steps
- Future annual vesting installments of the remaining 20 Restricted Stock Units.
Key Dates
| Date | Description |
|---|---|
| 07/17/2024 | Date 22,325 (30 post-splits) Restricted Stock Units (RSUs) were granted to Marvin L. White. |
| 07/17/2025 | Date of the first annual vesting installment of RSUs, resulting in the acquisition of 10 shares of common stock. |
| 07/21/2025 | Date the Form 4 filing was signed. |
Recommendation
holdKeywords
Aptevo Therapeutics, APVO, Marvin L. White, SEC Form 4, Insider Trading, Restricted Stock Units, RSU Vesting, Common Stock, Executive Compensation, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.